BUND FINANCE › Stocks › ONC
BeOne Medicines AG (ONC)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +8.65% above its 50-day average.
- It is +22.86% above its 200-day average (long-term uptrend).
- It sits at 88% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$1.2B | US$1.4B | US$2.5B | US$3.8B | US$5.3B |
| Net income | −US$1.5B | −US$2.0B | −US$881.7M | −US$644.8M | US$286.9M |
| EPS (diluted) | -15.21 | -19.37 | -8.45 | -6.12 | 2.53 |
| Gross margin | 86.0% | 79.8% | 84.6% | 84.4% | 87.5% |
| Operating margin | -122.3% | -126.4% | -49.1% | -14.9% | 8.4% |
| Net margin | -123.9% | -141.5% | -35.9% | -16.9% | 5.4% |
| Free cash flow | −US$1.6B | −US$2.0B | −US$1.8B | −US$669.8M | US$941.7M |
| Total debt | US$694.6M | US$596.7M | US$930.2M | US$1.1B | US$2.0B |
| Cash | US$4.4B | US$3.9B | US$3.2B | US$2.6B | US$4.5B |
Compound annual growth: revenue 46.0% · net income — (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 6.5x | 115.5x | 27.1x |
| EV / EBITDA | 27.0x | 49.6x | 16.5x |
| Operating margin | 17.8% | — | 3.6% |
| Net margin | 13.9% | — | -0.0% |
| Debt / equity | 0.70 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About BeOne Medicines AG
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice